Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2016

01-04-2016 | Case Report

Successful clozapine continuation during chemotherapy for the treatment of malignancy: a case report

Authors: Marloes R. Overbeeke, Marieke M. Beex-Oosterhuis, Ellen Graveland, Jannie N. den Hoed-van Wijk, Arthur R. Van Gool

Published in: International Journal of Clinical Pharmacy | Issue 2/2016

Login to get access

Abstract

Case

The need for chemotherapy treatment in a cancer patient who uses clozapine raises a clinical dilemma because both therapies can cause agranulocytosis. A 45-year-old male diagnosed with schizophrenia used clozapine together with zuclopenthixol for more than 15 years. Non-Hodgkin’s lymphoma was treated with chemotherapy twice, and clozapine was continued during both courses of chemotherapy. Agranulocytosis did not occur during the first treatment. During the second treatment, agranulocytosis occurred, but was attributed to chemotherapy, and blood counts recovered spontaneously. Successful concomitant use of clozapine and cancer chemotherapy is based on a limited number of case reports. However, two case reports describe persistent neutropenia or agranulocytosis, possibly related to this combination.

Conclusion

Clozapine should only be continued during cancer chemotherapy if favoured by the risk-to-benefit ratio.
Literature
1.
go back to reference Grover S, Hazari N, Chakrabarti S, Avasthi A. Delay in initiation of clozapine: a retrospective study from a tertiary care hospital in North India. Psychiatry Res. 2015;226(1):181–5.CrossRefPubMed Grover S, Hazari N, Chakrabarti S, Avasthi A. Delay in initiation of clozapine: a retrospective study from a tertiary care hospital in North India. Psychiatry Res. 2015;226(1):181–5.CrossRefPubMed
2.
go back to reference Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006;40(4):683–8.CrossRefPubMed Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006;40(4):683–8.CrossRefPubMed
4.
go back to reference Cunningham NT, Dennis N, Dattilo W, Hunt M, Bradford DW. Continuation of clozapine during chemotherapy: a case report and review of literature. Psychosomatics. 2014;55(6):673–9.CrossRefPubMed Cunningham NT, Dennis N, Dattilo W, Hunt M, Bradford DW. Continuation of clozapine during chemotherapy: a case report and review of literature. Psychosomatics. 2014;55(6):673–9.CrossRefPubMed
5.
go back to reference Sankaranarayanan A, Mulchandani M, Tirupati S. Clozapine, cancer chemotherapy and neutropenia—dilemmas in management. Psychiatr Danub. 2013;25(4):419–22.PubMed Sankaranarayanan A, Mulchandani M, Tirupati S. Clozapine, cancer chemotherapy and neutropenia—dilemmas in management. Psychiatr Danub. 2013;25(4):419–22.PubMed
6.
go back to reference Usta NG, Poyraz CA, Aktan M, Duran A. Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Ther Adv Psychopharmacol. 2014;4(6):276–81.CrossRefPubMedPubMedCentral Usta NG, Poyraz CA, Aktan M, Duran A. Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Ther Adv Psychopharmacol. 2014;4(6):276–81.CrossRefPubMedPubMedCentral
7.
go back to reference Deodhar JK, Prabhash K, Agarwal JP, Chaturvedi P. Clozapine and cancer treatment: adding to the experience and evidence. Indian J Psychiatry. 2014;56(2):191–3.CrossRefPubMedPubMedCentral Deodhar JK, Prabhash K, Agarwal JP, Chaturvedi P. Clozapine and cancer treatment: adding to the experience and evidence. Indian J Psychiatry. 2014;56(2):191–3.CrossRefPubMedPubMedCentral
8.
go back to reference Monga V, Broucek M, Amani M, Ramaswamy S. Clozapine and concomitant chemotherapy in a patient with schizophrenia and new onset esophageal cancer. Psychooncology. 2015;24(8):971–2.CrossRefPubMed Monga V, Broucek M, Amani M, Ramaswamy S. Clozapine and concomitant chemotherapy in a patient with schizophrenia and new onset esophageal cancer. Psychooncology. 2015;24(8):971–2.CrossRefPubMed
9.
go back to reference Goulet K, Grignon S. Case report: clozapine given in the context of chemotherapy for lung cancer. Psychooncology. 2008;17(5):512–6.CrossRefPubMed Goulet K, Grignon S. Case report: clozapine given in the context of chemotherapy for lung cancer. Psychooncology. 2008;17(5):512–6.CrossRefPubMed
10.
Metadata
Title
Successful clozapine continuation during chemotherapy for the treatment of malignancy: a case report
Authors
Marloes R. Overbeeke
Marieke M. Beex-Oosterhuis
Ellen Graveland
Jannie N. den Hoed-van Wijk
Arthur R. Van Gool
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 2/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0268-7

Other articles of this Issue 2/2016

International Journal of Clinical Pharmacy 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.